BE2013C051I2 - - Google Patents

Info

Publication number
BE2013C051I2
BE2013C051I2 BE2013C051C BE2013C051C BE2013C051I2 BE 2013C051 I2 BE2013C051 I2 BE 2013C051I2 BE 2013C051 C BE2013C051 C BE 2013C051C BE 2013C051 C BE2013C051 C BE 2013C051C BE 2013C051 I2 BE2013C051 I2 BE 2013C051I2
Authority
BE
Belgium
Application number
BE2013C051C
Other languages
French (fr)
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26545273&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2013C051(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of BE2013C051I2 publication Critical patent/BE2013C051I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BE2013C051C 1999-09-16 2013-07-22 BE2013C051I2 (sk)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP26185299 1999-09-16
JP2000130371 2000-04-28
PCT/JP2000/006258 WO2001019802A1 (fr) 1999-09-16 2000-09-13 Composes cycliques aromatiques azotes a six elements
EP00960979A EP1219609B1 (en) 1999-09-16 2000-09-13 Aromatic nitrogenous six-membered ring compounds

Publications (1)

Publication Number Publication Date
BE2013C051I2 true BE2013C051I2 (sk) 2019-10-16

Family

ID=26545273

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2013C051C BE2013C051I2 (sk) 1999-09-16 2013-07-22

Country Status (27)

Country Link
US (2) US6656935B2 (sk)
EP (1) EP1219609B1 (sk)
KR (1) KR100532546B1 (sk)
CN (2) CN102584799A (sk)
AR (1) AR025668A1 (sk)
AT (1) ATE358670T1 (sk)
AU (1) AU767558B2 (sk)
BE (1) BE2013C051I2 (sk)
BG (1) BG65453B1 (sk)
BR (1) BRPI0014526C1 (sk)
CA (1) CA2383466C (sk)
CY (2) CY1106534T1 (sk)
DE (1) DE60034239T2 (sk)
DK (1) DK1219609T3 (sk)
ES (1) ES2283315T3 (sk)
FR (1) FR13C0050I2 (sk)
HK (1) HK1044535A1 (sk)
HU (1) HU225917B1 (sk)
IL (2) IL148291A0 (sk)
LU (1) LU92249I2 (sk)
MY (1) MY123528A (sk)
NO (2) NO322038B1 (sk)
PT (1) PT1219609E (sk)
RU (1) RU2233273C3 (sk)
TR (1) TR200200701T2 (sk)
TW (1) TWI258471B (sk)
WO (1) WO2001019802A1 (sk)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US20080027037A1 (en) * 2000-04-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Cyclic compounds
US7273868B2 (en) * 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
US7220736B2 (en) * 2000-04-28 2007-05-22 Tanabe Seiyaku Co., Ltd. Pyrimidine compounds
NZ524572A (en) * 2000-09-06 2004-08-27 Tanabe Seiyaku Co Oral compositions comprising phosphodiesterase inhibitors ( PDE inhibitor )and an acidic substance such as fumaric acid with improved drug efficacy due to decrease solubility in neutral and alkaline regions
DK1330452T3 (da) * 2000-09-20 2009-03-16 Ortho Mcneil Janssen Pharm Pyrazinderivater som modulatorer af tyrosinkinaser
US6878714B2 (en) * 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US20020147198A1 (en) * 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US20030134836A1 (en) 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
US7927623B2 (en) 2001-02-15 2011-04-19 Mitsubishi Tanabe Pharma Corporation Tablets quickly disintegrated in oral cavity
AR036375A1 (es) * 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
ES2314106T3 (es) * 2001-10-17 2009-03-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Derivados de pirimidina, agentes farmaceuticos que contiene dichos compuestos, uso y metodo para su obtencion.
WO2003032994A2 (de) 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
DE60221627D1 (de) * 2001-12-21 2007-09-20 Virochem Pharma Inc Thiazolderivate und ihre Verwendung zur Behandlung oder Vorbeugung von Infektionen durch Flaviviren
MXPA04007191A (es) * 2002-01-23 2005-03-31 Bayer Pharmaceuticals Corp Derivados de pirimidina como inhibidores de rho-quinasa.
US7176310B1 (en) 2002-04-09 2007-02-13 Ucb Sa Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents
EP1503993A4 (en) * 2002-05-09 2006-05-03 Cytokinetics Inc COMPOUNDS, METHODS AND COMPOSITIONS
US7057042B2 (en) 2002-05-29 2006-06-06 Abbott Laboratories Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction
WO2003101994A1 (en) * 2002-05-29 2003-12-11 Abbott Laboratories Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction
AU2003250482A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Phthalimide derivatives as matrix metalloproteinase inhibitors
US7365070B2 (en) 2002-12-04 2008-04-29 Ore Pharmaceuticals Inc. Modulators of melanocortin receptor
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
KR100943555B1 (ko) * 2004-04-30 2010-02-22 워너-램버트 캄파니 엘엘씨 중추신경계 장애를 치료하기 위한 치환된 모르폴린 화합물
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US8648100B2 (en) 2005-04-19 2014-02-11 Takeda Gmbh Roflumilast for the treatment of pulmonary hypertension
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
US8247556B2 (en) 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
US20080051413A1 (en) * 2006-08-25 2008-02-28 Kaohsiung Medical University Nitrophenylpiperazine derivative of xanthine which relaxes tracheal airway and increases respiratory performance
CN101511364B (zh) 2006-09-07 2012-08-15 奈科明有限责任公司 用于糖尿病的治疗组合
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
TW200914457A (en) * 2007-05-31 2009-04-01 Kyowa Hakko Kogyo Kk Pyrimidodiazepinone derivative
JP5508258B2 (ja) 2007-06-04 2014-05-28 ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ トリアリール化合物および前記化合物を含む組成物
US8071557B2 (en) 2007-06-13 2011-12-06 Vivus, Inc. Treatment of pulmonary hypertension with carbonic anhydrase inhibitors
WO2009013286A1 (en) * 2007-07-24 2009-01-29 Novartis Ag Organic compounds
US8329691B2 (en) * 2007-10-15 2012-12-11 Takeda Pharmaceutical Company Limited Amide compounds and use of the same
EP2082768A1 (en) 2008-01-24 2009-07-29 Vectura Delivery Devices Limited Inhaler
EP2082771A1 (en) 2008-01-24 2009-07-29 Vectura Delivery Devices Limited Inhaler
EP2082767A1 (en) 2008-01-24 2009-07-29 Vectura Delivery Devices Limited Inhaler
EP2082766A1 (en) 2008-01-24 2009-07-29 Vectura Delivery Devices Limited Blister Strip Coil Forming
EP2082772A1 (en) 2008-01-24 2009-07-29 Vectura Delivery Devices Limited Inhaler
MX2010010209A (es) 2008-03-18 2010-10-05 Merck Sharp & Dohme 4-hidroxipirimidina-5-carboxamidas sustituidas.
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8586751B2 (en) 2009-06-12 2013-11-19 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
US8354593B2 (en) * 2009-07-10 2013-01-15 Nanocomp Technologies, Inc. Hybrid conductors and method of making same
GB0921481D0 (en) 2009-12-08 2010-01-20 Vectura Ltd Process and product
EP2361911A1 (en) * 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
EP2361912A1 (en) * 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
WO2011126250A2 (ko) 2010-04-05 2011-10-13 에스케이케미칼 주식회사 Pde5 억제제를 함유하는 피부 주름 개선용 조성물
CN101798301A (zh) * 2010-04-13 2010-08-11 漆又毛 吡咯烷基嘧啶甲磺酰胺衍生物及制备方法
TW201210584A (en) 2010-08-18 2012-03-16 Alcon Res Ltd Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma
CN102372697A (zh) * 2010-08-19 2012-03-14 山东轩竹医药科技有限公司 取代的嘧啶类化合物
US8980904B2 (en) * 2011-07-21 2015-03-17 Xuanzhu Pharma Co., Ltd. Heterocyclic substituted pyrimidine compound
WO2013067309A1 (en) 2011-11-04 2013-05-10 Xion Pharmaceutical Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2014026467A1 (zh) 2012-08-14 2014-02-20 山东轩竹医药科技有限公司 双环取代的嘧啶类化合物
BR112015012418A2 (pt) 2012-11-28 2017-07-11 Gruenenthal Gmbh carboxamidas específicas como moduladores de kcnq2/3
US9248122B2 (en) 2012-11-28 2016-02-02 Grünenthal GmbH Heteroquinoline-3-carboxamides as KCNQ2/3 modulators
CA2892658A1 (en) * 2012-11-28 2014-06-05 Grunenthal Gmbh Substituted amino-arylcarboxamides as kcnq2/3 modulators
CN104059025B (zh) * 2013-03-20 2017-07-04 广州朗圣药业有限公司 一种用于制备阿伐那非的中间体及其制备方法
BR112015025033B1 (pt) * 2013-03-29 2022-04-19 Xuanzhu Pharma Co., Ltd Composto e seu uso como inibidor de pde-5, bem como preparação farmacêutica compreeendendo o dito composto
WO2014174529A2 (en) * 2013-04-23 2014-10-30 Hetero Research Foundation Polymorphs of avanafil
CN103254180B (zh) * 2013-05-23 2014-07-23 苏州明锐医药科技有限公司 一种阿伐那非的制备方法
CN103265534B (zh) * 2013-05-23 2014-07-23 苏州明锐医药科技有限公司 阿伐那非的制备方法
CN103254179B (zh) * 2013-05-23 2014-09-10 苏州明锐医药科技有限公司 阿伐那非的制备方法
WO2014187273A1 (zh) * 2013-05-23 2014-11-27 苏州明锐医药科技有限公司 阿伐那非的制备方法
WO2015001567A1 (en) * 2013-07-01 2015-01-08 Msn Laboratories Private Limited Process for the preparation of (s)-4-[(3-chloro-4-methoxybenzyl)amino]-2-[2- (hydroxymethyl)-1-pyrrolidinyl]-n-(2-pyrimidinyl methyl-5-pyrimidine carboxamide
CN104557877B (zh) * 2013-10-28 2016-08-17 重庆安格龙翔医药科技有限公司 一种阿伐那非中间体及其制备方法和应用
CR20160207A (es) 2013-11-05 2016-08-10 Ben Gurion Univ Of The Negev Res And Dev Authority Compuestos para el tratamiento de la diabetes y las complicaciones que surgen de la misma enfermedad
CN104628707A (zh) * 2013-11-13 2015-05-20 北大方正集团有限公司 一种阿伐那非的无定型及其制备方法、用途和药物组合物
CN104628708A (zh) * 2013-11-13 2015-05-20 北大方正集团有限公司 一种阿伐那非的晶型及其制备方法、用途和药物组合物
CN104650045B (zh) * 2013-11-19 2017-04-19 苏州旺山旺水生物医药有限公司 阿伐那非的制备方法
GB201321748D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
CN103833736A (zh) * 2014-03-04 2014-06-04 北京澳合药物研究院有限公司 一种阿伐那非的制备方法
WO2015177807A1 (en) * 2014-05-22 2015-11-26 Wanbury Ltd. A process for the preparation of avanafil and its novel intermediates
CN104003981A (zh) * 2014-05-28 2014-08-27 河北康泰药业有限公司 阿伐那非的合成方法
CN104151299B (zh) * 2014-08-22 2017-03-08 北京科莱博医药开发有限责任公司 化合物、晶型化合物及其制备方法
CN104356115B (zh) * 2014-11-21 2016-08-24 齐鲁天和惠世制药有限公司 一种4-[(3-氯-4-甲氧基苄基)氨基]-2-[2-(羟甲基)-1-吡咯烷基]嘧啶-5-羧酸乙酯的制备方法
CN104530015B (zh) * 2014-12-10 2017-01-04 齐鲁天和惠世制药有限公司 一种阿伐那非的制备方法
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CN105924402A (zh) * 2016-05-06 2016-09-07 蚌埠中实化学技术有限公司 一种2-胺基甲基嘧啶盐酸盐的制备方法
CN109476645A (zh) 2016-07-14 2019-03-15 辉瑞大药厂 作为vanin-1酶抑制剂的新的嘧啶甲酰胺
CN106496201A (zh) * 2016-10-31 2017-03-15 昆药集团股份有限公司 一种阿伐那非原料药的制备方法
CN110381951A (zh) 2016-12-14 2019-10-25 瑞必治公司 用于治疗肺性高血压和其他肺病症的方法及组合物
CN107879986A (zh) * 2017-12-20 2018-04-06 重庆英斯凯化工有限公司 一种阿伐那非杂质的合成方法
CN108658872B (zh) * 2018-05-03 2021-06-22 无锡富泽药业有限公司 一种阿伐那非中间体的制备方法
BR112021001950A2 (pt) 2018-08-06 2021-04-27 Nicox S.A. inibidor de fosfodiesterase tipo 5 liberador de óxido nítrico
CN109280049B (zh) * 2018-09-25 2021-02-02 重庆奥舍生物化工有限公司 一种医药化合物阿伐那非的合成方法
CN109776505B (zh) * 2019-03-14 2021-07-27 扬州市三药制药有限公司 一种阿伐那非的制备方法
CN110078713B (zh) * 2019-04-10 2021-06-04 北京精华耀邦医药科技有限公司 一种用于治疗男性勃起功能障碍的化合物
CN110117274A (zh) * 2019-05-08 2019-08-13 梯尔希（南京）药物研发有限公司 一种阿伐那非杂质的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1229413A (sk) * 1967-06-14 1971-04-21
JPS5481299A (en) * 1977-12-09 1979-06-28 Daito Koeki Kk Preparation of 2,8-disubstituted-6-formyl-5,8-dihydro-5- oxopyrido 2,3-d pyrimidine derivative
AT392789B (de) * 1985-01-23 1991-06-10 Toyama Chemical Co Ltd Verfahren zur herstellung von 1-substituierten aryl-1,4-dihydro-4-oxonaphthyridinderivaten
DE3752141T2 (de) * 1986-02-24 1998-03-26 Mitsui Petrochemical Ind Mittel zur behandlung von neuropathie
DE69115126T2 (de) 1990-05-16 1996-05-09 Tomoegawa Paper Mfg Co Ltd Leitfähiges Substrat und seine Verwendung in den Druckmedien.
GB9012316D0 (en) 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
US5252604A (en) 1992-07-10 1993-10-12 Hoffmann-La Roche Inc. Compositions of retinoic acids and tocopherol for prevention of dermatitis
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
DK0640599T3 (da) * 1993-08-26 1998-09-28 Ono Pharmaceutical Co 4-Aminopyrimidin-derivater
WO1995018097A1 (fr) 1993-12-27 1995-07-06 Eisai Co., Ltd. Derive de l'acide anthranilique
ES2224130T3 (es) 1994-08-09 2005-03-01 Eisai Co., Ltd. Compuesto de piridazina condensada.
KR100239800B1 (ko) 1996-11-28 2000-03-02 손경식 4,5-디아미노 피리미딘 유도체 및 이의 제조방법
JP2000072751A (ja) * 1998-08-26 2000-03-07 Tanabe Seiyaku Co Ltd イソキノリノン誘導体
IL132406A0 (en) 1998-10-21 2001-03-19 Pfizer Prod Inc Treatment of bph with cgmp elevators
GB9823101D0 (en) * 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds

Also Published As

Publication number Publication date
AU7311800A (en) 2001-04-17
HUP0202795A2 (hu) 2003-02-28
RU2233273C3 (ru) 2019-07-17
DK1219609T3 (da) 2007-05-21
US20030032647A1 (en) 2003-02-13
KR20020047170A (ko) 2002-06-21
CN1374953A (zh) 2002-10-16
AR025668A1 (es) 2002-12-11
NO2013018I1 (no) 2014-06-02
ATE358670T1 (de) 2007-04-15
MY123528A (en) 2006-05-31
EP1219609A4 (en) 2002-11-06
EP1219609B1 (en) 2007-04-04
LU92249I9 (sk) 2019-01-03
BG65453B1 (bg) 2008-08-29
DE60034239D1 (de) 2007-05-16
CY2013034I1 (el) 2016-04-13
HK1044535A1 (en) 2002-10-25
BR0014526A (pt) 2002-06-18
BRPI0014526B8 (pt) 2017-03-21
NO20021308L (no) 2002-04-24
HU225917B1 (en) 2007-12-28
BR0014526B1 (pt) 2013-09-10
LU92249I2 (fr) 2013-09-10
CY1106534T1 (el) 2012-01-25
PT1219609E (pt) 2007-06-19
IL148291A (en) 2006-10-05
US20030229095A1 (en) 2003-12-11
BRPI0014526C1 (pt) 2021-05-25
IL148291A0 (en) 2002-09-12
ES2283315T3 (es) 2007-11-01
US6656935B2 (en) 2003-12-02
AU767558B2 (en) 2003-11-13
FR13C0050I2 (fr) 2014-04-11
FR13C0050I1 (sk) 2013-09-27
CY2013034I2 (el) 2017-03-15
HUP0202795A3 (en) 2003-03-28
CN102584799A (zh) 2012-07-18
TWI258471B (en) 2006-07-21
TR200200701T2 (tr) 2002-06-21
DE60034239T2 (de) 2007-12-27
NO2013018I2 (no) 2015-01-12
WO2001019802A1 (fr) 2001-03-22
CA2383466A1 (en) 2001-03-22
BG106566A (en) 2003-02-28
US6797709B2 (en) 2004-09-28
RU2233273C2 (ru) 2004-07-27
KR100532546B1 (ko) 2005-12-01
NO20021308D0 (no) 2002-03-15
NO322038B1 (no) 2006-08-07
EP1219609A1 (en) 2002-07-03
CA2383466C (en) 2009-08-25

Similar Documents

Publication Publication Date Title
BE2018C020I2 (sk)
BE2015C057I2 (sk)
BE2016C007I2 (sk)
BE2015C018I2 (sk)
BE2014C017I2 (sk)
BE2013C051I2 (sk)
BE2013C020I2 (sk)
BE2013C015I2 (sk)
BE2013C001I2 (sk)
BE2012C036I2 (sk)
BE2011C004I2 (sk)
BE2010C011I2 (sk)
BE2008C046I2 (sk)
BE1025464I2 (sk)
BRPI0017527B8 (sk)
BE2008C047I2 (sk)
BRPI0001672A2 (sk)
BRPI0001542A2 (sk)
BRPI0012675B8 (sk)
BRPI0017522A2 (sk)
BRMU7902607U2 (sk)
CN3098146S (sk)
CN3099878S (sk)
CN3099353S (sk)
AU2000278349A8 (sk)